文献速递浆细胞疾病

帕博利珠单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤:KEYNOTE-185随机对照3期试验

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2019-07-18

KEYNOTE-185是一项在15国95中心开展的随机开放标签3期试验,纳入301例不适合移植的初治多发性骨髓瘤患者,比较帕博利珠单抗联合来那度胺和地塞米松与来那度胺和地塞米松单用。因组间死亡比例失衡,FDA要求提前终止并开展非计划中期分析;结果显示联合组严重不良事件和治療相关死亡均高于单用组,获益-风险不利。

要点

  • 帕博利珠单抗联合来那度胺和地塞米松组严重不良事件发生率54%,高于单用组的39%。
  • 联合组治疗相关死亡6例(4%),单用组2例(1%)。

核心结论

  • 非计划中期分析显示,帕博利珠单抗联合来那度胺和地塞米松对初治多发性骨髓瘤患者的获益-风险不利。

研究设计与样本

  • 随机、开放标签、3期试验,在15个国家95个医学中心开展。
  • 纳入301例不适合移植的初治多发性骨髓瘤患者,随机1:1分配至联合组(n=151)或单用组(n=150)。
  • 主要终点为研究者评估的无进展生存期,因试验提前终止而采用研究者评估。

主要发现

  • 严重不良事件联合组81例(54%)vs 单用组57例(39%)。
  • 联合组最常见严重不良事件为肺炎9例(6%)和发热7例(5%);单用组为肺炎8例(6%)和脓毒症2例(1%)。
  • 治疗相关死亡联合组6例(4%),单用组2例(1%)。

关键数值与推荐

  • 来那度胺25 mg口服,第1-21天;地塞米松40 mg口服,第1、8、15、22天;28天为一周期。
  • 帕博利珠单抗200 mg静脉注射,每3周一次。
  • 联合组治疗相关死亡原因:心脏骤停、心脏衰竭、心肌炎、大肠穿孔、肺炎、肺栓塞。
  • 单用组治疗相关死亡原因:上消化道出血、呼吸衰竭。

临床怎么用

  • 该联合方案在初治多发性骨髓瘤患者中获益-风险不利,长期安全性和生存随访仍在进行。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment efficacy. KEYNOTE-185 assessed the efficacy and safety of lenalidomide and dexamethasone with and without pembrolizumab in patients with previously untreated multiple myeloma. Here, we present the results of an unplanned interim analysis done to assess the benefit-risk of the combination at the request of the US Food and Drug Administration (FDA). METHODS: KEYNOTE-185 was a randomised, open-label, phase 3 trial done at 95 medical centres across 15 countries (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, New Zealand, Norway, Russia, South Africa, Spain, UK, and USA). Transplantation-ineligible patients aged 18 years and older with newly diagnosed multiple myeloma, Eastern Cooperative Oncology Group performance status of 0 or 1, and who were treatment naive were enrolled, and randomly assigned 1:1 to receive either pembrolizumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone alone using an interactive voice or integrated web response system. Patients received oral lenalidomide 25 mg on days 1-21 and oral dexamethasone 40 mg on days 1, 8, 15, and 22 of repeated 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The primary endpoint was progression-free survival, which was investigator-assessed because of early trial termination. Efficacy was analysed in all randomly assigned patients and safety was analysed in all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, number NCT02579863, and it is closed for accrual. FINDINGS: Between Jan 7, 2016, and June 9, 2017, 301 patients were randomly assigned to the pembrolizumab plus lenalidomide and dexamethasone group (n=151) or the lenalidomide and dexamethasone group (n=150). On July 3, 2017, the FDA decided to halt the study because of the imbalance in the proportion of death between groups. At database cutoff (June 2, 2017), with a median follow-up of 6·6 months (IQR 3·4-9·6), 149 patients in the pembrolizumab plus lenalidomide and dexamethasone group and 145 in the lenalidomide and dexamethasone group had received their assigned study drug. Median progression-free survival was not reached in either group; progression-free survival estimates at 6-months were 82·0% (95% CI 73·2-88·1) versus 85·0% (76·8-90·5; hazard ratio [HR] 1·22; 95% CI 0·67-2·22; p=0·75). Serious adverse events were reported in 81 (54%) patients in the pembrolizumab plus lenalidomide and dexamethasone group versus 57 (39%) patients in the lenalidomide and dexamethasone group; the most common serious adverse events were pneumonia (nine [6%]) and pyrexia (seven [5%]) in the pembrolizumab plus lenalidomide and dexamethasone group and pneumonia (eight [6%]) and sepsis (two [1%]) in the lenalidomide and dexamethasone group. Six (4%) treatment-related deaths occurred in the pembrolizumab plus lenalidomide and dexamethasone group (cardiac arrest, cardiac failure, myocarditis, large intestine perforation, pneumonia, and pulmonary embolism) and two (1%) in the lenalidomide and dexamethasone group (upper gastrointestinal haemorrhage and respiratory failure). INTERPRETATION: The results from this unplanned, FDA-requested, interim analysis showed that the benefit-risk profile of pembrolizumab plus lenalidomide and dexamethasone is unfavourable for patients with newly diagnosed, previously untreated multiple myeloma. Long-term safety and survival follow-up is ongoing. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc (Kenilworth, NJ, USA).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019. PMID: 31327689. doi:10.1016/S2352-3026(19)30109-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。